{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:20:30Z","timestamp":1793910030143,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST104-3114-Y-368-002"],"award-info":[{"award-number":["MOST104-3114-Y-368-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST106-0210-01-15-02"],"award-info":[{"award-number":["MOST106-0210-01-15-02"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST106-0210-01-15-04"],"award-info":[{"award-number":["MOST106-0210-01-15-04"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW106-TDU-B-212-134004"],"award-info":[{"award-number":["MOHW106-TDU-B-212-134004"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4229-5","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T02:49:04Z","timestamp":1522810144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Germline breast cancer susceptibility gene mutations and breast cancer outcomes"],"prefix":"10.1186","volume":"18","author":[{"given":"Yong Alison","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhih-Wei","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Fang","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Pin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chun Skye","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Suei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"4229_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.20892\/j.issn.2095-3941.2016.0002","volume":"13","author":"C Stanislaw","year":"2016","unstructured":"Stanislaw C, Xue Y, Wilcox WR. Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer biology & medicine. 2016;13:55\u201367.","journal-title":"Cancer biology & medicine"},{"key":"4229_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1053\/j.seminoncol.2016.10.001","volume":"43","author":"EF Cobain","year":"2016","unstructured":"Cobain EF, Milliron KJ, Merajver SD. Updates on breast cancer genetics: clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. Semin Oncol. 2016;43:528\u201335.","journal-title":"Semin Oncol"},{"key":"4229_CR3","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for Cancer susceptibility. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33:3660\u20137.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"4229_CR4","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32:2001\u20139.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"4229_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"1","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, et al. Clinical Actionability of multigene panel testing for hereditary breast and ovarian Cancer risk assessment. JAMA oncology. 2015;1:943\u201351.","journal-title":"JAMA oncology"},{"key":"4229_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","volume":"34","author":"ER Thompson","year":"2016","unstructured":"Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al. Panel testing for familial breast Cancer: calibrating the tension between research and clinical care. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34:1455\u20139.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"4229_CR7","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-Cancer risk. N Engl J Med. 2015;372:2243\u201357.","journal-title":"N Engl J Med"},{"key":"4229_CR8","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2217\/fon-2016-0116","volume":"12","author":"G Roviello","year":"2016","unstructured":"Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, et al. A phase II study of olaparib in breast cancer patients: biological evaluation from a \u2018window of opportunity\u2019 trial. Future oncology (London, England). 2016;12:2189\u201393.","journal-title":"Future oncology (London, England)"},{"key":"4229_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa070608","volume":"357","author":"G Rennert","year":"2007","unstructured":"Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:115\u201323.","journal-title":"N Engl J Med"},{"key":"4229_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","volume":"43","author":"CT Brekelmans","year":"2007","unstructured":"Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1\/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867\u201376.","journal-title":"Eur J Cancer"},{"key":"4229_CR11","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/bcr658","volume":"6","author":"ME Robson","year":"2004","unstructured":"Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment. Breast cancer research: BCR. 2004;6:R8\u2013r17.","journal-title":"Breast cancer research: BCR"},{"key":"4229_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/PPO.0b013e318238f579","volume":"17","author":"KL Smith","year":"2011","unstructured":"Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer journal (Sudbury, Mass). 2011;17:492\u20139.","journal-title":"Cancer journal (Sudbury, Mass)"},{"key":"4229_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejca.2006.07.019","volume":"43","author":"FP Liebens","year":"2007","unstructured":"Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1\/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238\u201357.","journal-title":"Eur J Cancer"},{"key":"4229_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","volume":"119","author":"L Bordeleau","year":"2009","unstructured":"Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2009;119:13.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004975","volume":"95","author":"Z Baretta","year":"2016","unstructured":"Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95:e4975.","journal-title":"Medicine"},{"key":"4229_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-016-4003-9","volume":"160","author":"R Graffeo","year":"2016","unstructured":"Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 2016;160:393\u2013410.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between Cancer predisposition testing panel genes and breast Cancer. JAMA oncology. 2017;3:1190\u20136.","journal-title":"JAMA oncology"},{"key":"4229_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10549-011-1543-x","volume":"129","author":"A Romero","year":"2011","unstructured":"Romero A, Perez-Segura P, Tosar A, Garcia-Saenz JA, Diaz-Rubio E, Caldes T, et al. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat. 2011;129:939\u201346.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10549-011-1677-x","volume":"130","author":"M Vuorela","year":"2011","unstructured":"Vuorela M, Pylkas K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wappling A, et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat. 2011;130:1003\u201310.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/humu.21625","volume":"33","author":"ER Thompson","year":"2012","unstructured":"Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat. 2012;33:95\u20139.","journal-title":"Hum Mutat"},{"key":"4229_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/jmedgenet-2012-100852","volume":"49","author":"LM Pelttari","year":"2012","unstructured":"Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, et al. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet. 2012;49:429\u201332.","journal-title":"J Med Genet"},{"key":"4229_CR22","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/cas.13350","volume":"108","author":"K Sato","year":"2017","unstructured":"Sato K, Koyasu M, Nomura S, Sato Y, Kita M, Ashihara Y, et al. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Cancer Sci. 2017;108:2287\u201394.","journal-title":"Cancer Sci"},{"key":"4229_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304\u201311.","journal-title":"J Clin Oncol"},{"key":"4229_CR24","first-page":"2113","volume":"5","author":"M Ollier","year":"2015","unstructured":"Ollier M, Radosevic-Robin N, Kwiatkowski F, Ponelle F, Viala S, Privat M, et al. DNA repair genes implicated in triple negative familial non-BRCA1\/2 breast cancer predisposition. Am J Cancer Res. 2015;5:2113\u201326.","journal-title":"Am J Cancer Res"},{"key":"4229_CR25","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/bcr3669","volume":"16","author":"F Damiola","year":"2014","unstructured":"Damiola F, Pertesi M, Oliver J, Le Calvez-Kelm F, Voegele C, Young EL, et al. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a breast Cancer family registry case-control mutation-screening study. Breast Cancer Res. 2014;16:R58.","journal-title":"Breast Cancer Res"},{"key":"4229_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/jmedgenet-2015-103216","volume":"52","author":"EF Harkness","year":"2015","unstructured":"Harkness EF, Barrow E, Newton K, Green K, Clancy T, Lalloo F, et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet. 2015;52:553\u20136.","journal-title":"J Med Genet"},{"key":"4229_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ejmg.2015.09.005","volume":"58","author":"L Maresca","year":"2015","unstructured":"Maresca L, Spugnesi L, Lodovichi S, Cozzani C, Naccarato AG, Tancredi M, et al. MSH2 role in BRCA1-driven tumorigenesis: a preliminary study in yeast and in human tumors from BRCA1-VUS carriers. Eur J Med Genet. 2015;58:531\u20139.","journal-title":"Eur J Med Genet"},{"key":"4229_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/jmedgenet-2017-104542","volume":"54","author":"M Goldberg","year":"2017","unstructured":"Goldberg M, Bell K, Aronson M, Semotiuk K, Pond G, Gallinger S, et al. Association between the lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry. J Med Genet. 2017;54:742\u20136.","journal-title":"J Med Genet"},{"key":"4229_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-014-2991-x","volume":"146","author":"S Haricharan","year":"2014","unstructured":"Haricharan S, Bainbridge MN, Scheet P, Brown PH. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat. 2014;146:211\u201320.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jmedgenet-2015-103529","volume":"53","author":"DF Easton","year":"2016","unstructured":"Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet. 2016;53:298\u2013309.","journal-title":"J Med Genet"},{"key":"4229_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jmg.2007.049346","volume":"44","author":"S Sharif","year":"2007","unstructured":"Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet. 2007;44:481\u20134.","journal-title":"J Med Genet"},{"key":"4229_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/bjc.2016.403","volume":"116","author":"E Uusitalo","year":"2017","unstructured":"Uusitalo E, Kallionpaa RA, Kurki S, Rantanen M, Pitkaniemi J, Kronqvist P, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer. 2017;116:211\u20137.","journal-title":"Br J Cancer"},{"key":"4229_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ejhg.2008.212","volume":"17","author":"T Ripperger","year":"2009","unstructured":"Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. European journal of human genetics : EJHG. 2009;17:722\u201331.","journal-title":"European journal of human genetics : EJHG"},{"key":"4229_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25\u201333.","journal-title":"Cancer"},{"key":"4229_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast Cancer linkage consortium. Am J Hum Genet. 1998;62:676\u201389.","journal-title":"Am J Hum Genet"},{"key":"4229_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-011-1596-x","volume":"132","author":"J Zhang","year":"2012","unstructured":"Zhang J, Pei R, Pang Z, Ouyang T, Li J, Wang T, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat. 2012;132:421\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2188\/jea.JE20120043","volume":"23","author":"W Cao","year":"2013","unstructured":"Cao W, Wang X, Li JC. Hereditary breast cancer in the Han Chinese population. Journal of epidemiology \/ Japan Epidemiological Association. 2013;23:75\u201384.","journal-title":"Journal of epidemiology \/ Japan Epidemiological Association"},{"key":"4229_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-008-0181-4","volume":"116","author":"NY Rao","year":"2009","unstructured":"Rao NY, Hu Z, Yu JM, Li WF, Zhang B, Su FX, et al. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. Breast Cancer Res Treat. 2009;116:563\u201370.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/jhg.2011.142","volume":"57","author":"WH Kuo","year":"2012","unstructured":"Kuo WH, Lin PH, Huang AC, Chien YH, Liu TP, Lu YS, et al. Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. J Hum Genet. 2012;57:130\u20138.","journal-title":"J Hum Genet"},{"key":"4229_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4048\/jbc.2013.16.4.357","volume":"16","author":"H Kim","year":"2013","unstructured":"Kim H, Choi DH. Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast Cancer. J Breast Cancer. 2013;16:357\u201365.","journal-title":"J Breast Cancer"},{"key":"4229_CR41","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.18632\/oncotarget.7027","volume":"7","author":"PH Lin","year":"2016","unstructured":"Lin PH, Kuo WH, Huang AC, Lu YS, Lin CH, Kuo SH, et al. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget. 2016;7:8310\u201320.","journal-title":"Oncotarget"},{"key":"4229_CR42","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/npjgenmed.2015.3","volume":"1","author":"ESY Wong","year":"2016","unstructured":"Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. Npj. Genomic Medicine. 2016;1:15003.","journal-title":"Genomic Medicine"},{"key":"4229_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10689-012-9531-9","volume":"11","author":"MA de Bruin","year":"2012","unstructured":"de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, et al. Breast cancer risk factors differ between Asian and white women with BRCA1\/2 mutations. Familial Cancer. 2012;11:429\u201339.","journal-title":"Familial Cancer"},{"key":"4229_CR44","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/nar\/gkj518","volume":"34","author":"E Mathe","year":"2006","unstructured":"Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res. 2006;34:1317\u201325.","journal-title":"Nucleic Acids Res"},{"key":"4229_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248\u20139.","journal-title":"Nat Methods"},{"key":"4229_CR46","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073\u201381.","journal-title":"Nat Protoc"},{"key":"4229_CR47","doi-asserted-by":"publisher","first-page":"e46688","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and Indels. PLoS One. 2012;7:e46688.","journal-title":"PLoS One"},{"key":"4229_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310\u20135.","journal-title":"Nat Genet"},{"key":"4229_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12859-014-0428-5","volume":"16","author":"F Reinecke","year":"2015","unstructured":"Reinecke F, Satya RV, DiCarlo J. Quantitative analysis of differences in copy numbers using read depth obtained from PCR-enriched samples and controls. BMC bioinformatics. 2015;16:17.","journal-title":"BMC bioinformatics"},{"key":"4229_CR50","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/bioinformatics\/btu436","volume":"30","author":"V Boeva","year":"2014","unstructured":"Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 2014;30:3443\u201350.","journal-title":"Bioinformatics"},{"key":"4229_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497\u2013506.","journal-title":"N Engl J Med"},{"key":"4229_CR52","unstructured":"NCCN Clinical Practice Guidelines in Oncology - Genetic\/Familial High-Risk Assessment: Breast and Ovarian Version 2.2017. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf ."},{"key":"4229_CR53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10549-012-2292-1","volume":"136","author":"A Kwong","year":"2012","unstructured":"Kwong A, Ng EKO, Law FBF, Wong HN, Wa A, Wong CLP, et al. Novel BRCA1 and BRCA2 genomic rearrangements in southern Chinese breast\/ovarian cancer patients. Breast Cancer Res Treat. 2012;136:931\u20133.","journal-title":"Breast Cancer Res Treat"},{"key":"4229_CR54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10689-009-9279-z","volume":"8","author":"MW Seong","year":"2009","unstructured":"Seong MW, Cho SI, Noh DY, Han W, Kim SW, Park CM, et al. Low contribution of BRCA1\/2 genomic rearrangement to high-risk breast cancer in the Korean population. Familial Cancer. 2009;8:505\u20138.","journal-title":"Familial Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4229-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T23:49:47Z","timestamp":1604101787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4229"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4229-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"17 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board Committee at Koo Foundation Sun Yat-Sen Cancer Center (case No. 20141222A). Written informed consent was obtained from each study participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"315"}}